INtRON Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 11, 2023 at 12:26 pm IST
Share
iNtRON Biotechnology, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported negative sales was KRW 0.00052 million compared to KRW 0.00007 million a year ago. Net loss was KRW 1,847.33 million compared to net income of KRW 12,176.19 million a year ago. Basic loss per share from continuing operations was KRW 56 compared to basic earnings per share from continuing operations of KRW 357 a year ago. Diluted loss per share from continuing operations was KRW 56 compared to KRW 130 a year ago. Basic loss per share was KRW 56 compared to basic earnings per share of KRW 357 a year ago. Diluted loss per share was KRW 1 compared to KRW 130 a year ago.
For the six months, sales was KRW 0.59301 million compared to KRW 1.02 million a year ago. Net loss was KRW 3,400.71 million compared to net income of KRW 10,962.87 million a year ago. Basic loss per share from continuing operations was KRW 102 compared to basic earnings per share from continuing operations of KRW 322 a year ago. Diluted loss per share from continuing operations was KRW 102 compared to KRW 17 a year ago. Basic loss per share was KRW 102 compared to basic earnings per share of KRW 322 a year ago. Diluted loss per share was KRW 7 compared to KRW 17 a year ago.
iNtRON Biotechnology, Inc. is a Korea-based company principally engaged in the biotechnology industry. The Company operates its business through two main divisions: genetic reagent division and molecular diagnostics division. Its genetic reagent division is involved in the research and development of reagents, which are under the brand names of Maxime and pLUG for life science research. Its molecular diagnostics division is engaged in the development and production of nucleic acid tester for infectious diseases. It also engages in the operation of veterinary antibiotic alternative business and new biopharmaceuticals development business. The Company distributes its products within domestic market and to overseas markets.
INTRON BIOTECHNOLOGY, INC. 
